

**EXPRESSION OF *STK15*, *CENPW* AND *TIMP1*
GENES IN BREAST AND COLORECTAL CANCERS
FROM HUMAN BLOOD SAMPLES**



LUCKY GOH POH WAH

UMMS
UNIVERSITI MALAYSIA SABAH

**FACULTY OF SCIENCE AND NATURAL RESOURCES
UNIVERSITI MALAYSIA SABAH
2015**

**EXPRESSION OF *STK15*, *CENPW* AND *TIMP1*
GENES IN BREAST AND COLORECTAL
CANCERS FROM HUMAN BLOOD SAMPLES**

LUCKY GOH POH WAH



**THIS IS SUBMITTED IN PARTIAL
FULFILLMENT OF THE REQUIREMENTS FOR
THE DEGREE OF MASTER OF SCIENCE**


**FACULTY OF SCIENCE AND NATURAL
RESOURCES
UNIVERSITI MALAYSIA SABAH
2015**

DECLARATION

I hereby declare that the material in this thesis is my own except for quotations, equations, summaries and references, which have been duly acknowledged.

26 August 2015

Lucky Goh Poh Wah
MS1321012T



UMS
UNIVERSITI MALAYSIA SABAH

SUPERVISOR CONFIRMATION

NAME : **LUCKY GOH POH WAH**
MATRIC NO. : **MS1321012T**
TITLE : **EXPRESSION OF *STK15*, *CENPW* and *TIMP1* GENES IN BREAST AND COLORECTAL CANCERS FROM HUMAN BLOOD SAMPLES**
DEGREE : **MASTER OF SCIENCE (BIOTECHNOLOGY)**
VIVA DATE : **30th July 2015**


CERTIFIED BY

1.

SUPERVISOR

(Assoc. Prof. Dr. Lee Ping Chin)

Signature



UMMS
UNIVERSITI MALAYSIA SABAH

ACKNOWLEDGEMENT

The work presented in this thesis was performed at University Malaysia Sabah (UMS) and supported by University of Malaya, Research Collaborative Grant CG041-2013. I also appreciate the MyBrain15 scholarship by Ministry of Education Malaysia to allow the completion of this Master degree.

I would like to thank my supervisor associate professor Dr Lee Ping Chin for her guidance and patience in this study. I am also very grateful for the collaboration from Dr Edwin See Un Hean at the Department of Surgery, Queen Elizabeth Hospital, Sabah for assistance in sample collection.

I am thankful to my lab colleagues for their willingness to share their knowledge and idea. Finally, I would like to express my sincere gratitude to my family for their support and encouragement throughout this study.

Lucky Goh Poh Wah
August 2015



UMS
UNIVERSITI MALAYSIA SABAH

ABSTRACT

Cancer is one of the highest incidence and mortality worldwide. Despite the great information on cancer, particularly in breast cancer (BC) and colorectal cancer (CRC), the rate of BC and CRC incidence and deaths remains alarming. This pilot case-control study is conducted to further understand the biology of cancer especially in mRNA/gene expression aspect using whole blood system by analyzing the differential gene expression of three potential BC and CRC related genes which were *STK15*, *CENPW*, and *TIMP1*. Whole blood samples were collected from 31 healthy individuals and 36 cancer patients (14 BC and 22 CRC) followed by total RNA isolation using Tempus™ Blood RNA System. The RNA integrity number (RIN) of extracted RNA was determined using bioanalyzer. Gene expression analysis was performed with 5'-hydrolysis probes in triplicates using real-time PCR. Additionally, influence of other factors such as age, gender, and gene polymorphism to gene expression were also evaluated in this study. Statistical Mann-Whitney *U*-test was applied to determine the differential expressions of *STK15*, *CENPW* and *TIMP1* normalized to two reference genes (*GAPDH* and *HPRT1*) in BC and CRC patients, with $p < 0.05$ as statistical significant. This study showed that the extracted total RNA was highly intact with $RIN > 7.0$ for reliable gene expression analysis. *STK15* expression was significantly ($p < 0.05$) downregulated in CRC regardless of both age and gender. Interestingly, a significant ($p < 0.05$) reduction of *STK15* expression of BC were found in age ≥ 50 but not in age < 50 suggesting an age related factor in BC and not in CRC. No significant difference was observed in the downregulation of *CENPW* and *TIMP1* gene expression in BC and CRC. Further investigation based on genotyping of the *STK15* Phe31Ile polymorphism showed that *STK15* expression in BC was non-significantly ($p > 0.05$) downregulated after samples were grouped according to genotypes (*Phe/Phe*, *Phe/Ile*, and *Ile/Ile*), but significant ($p < 0.05$) downregulation was observed in CRC patients carrying homozygous wild-type (*Phe/Phe*) or homozygous variant (*Ile/Ile*) genotypes. This indicated *Phe/Phe* or *Ile/Ile* genotype in *STK15* Phe31Ile polymorphism associated to reduce *STK15* expression in CRC but not in BC. In summary, the reduced *STK15* expressions of this study provide an initial insight of using blood-based biomarker for BC and CRC.

ABSTRAK

EXPRESI GEN STK15, CENPW DAN TIMP1 DALAM KANSER PAYU DARA DAN KOLOREKTAL DARIPADA SAMPEL DARAH MANUSIA

Kanser adalah salah satu factor kejadian tertinggi dan kematian di dunia. Walaupun kemajuan dalam ilmu terhadap kanser, terutamanya dalam kanser payu dara dan kolorektal, kadar kejadian dan kematian kanser masih meningkat masih meningkat setiap tahun termasuk Malaysia. Kajian kes-kawalan ini dijalankan untuk lebih mamahami kanser biologi terutamanya ekspresi mRNA/gen dalam darah, dengan menganalisa kelainan tiga kanser-kaitan ekspresi gen termasuk STK15, CENPW, dan TIMP1 dalam pesakit kanser payu dara dan kolorektal. Sampel darah telah dikumpul daripada 31 sukarelawan sihat dan 36 pesakit kanser (14 kanser payu dara dan 22 pesakit kolorektal) diikuti dengan isolasi RNA menggunakan Tempus™ Blood RNA System. RNA integrity number (RIN) RNA yang telah diestrak telah ditentukan dengan menggunakan bioanalyzer. Ekspresi gen telah dilaksanakan dengan 5' probe hydrolysis dalam tiga replika menggunakan real-time PCR. Selain itu, pengaruh factor lain seperti, umur, jantina, dan polimorfisme gen terhadap ekspresi gen telah dinilai dalam kajian ini. Analisis statistik dilakukan dengan menggunakan Mann-Whitney U-tests dalam SPSS V17.0 untuk menentukan kelainan gen ekspresi STK15, CENPW dan TIMP1 dinormalisasi kepada gen rujukan di pra-tentukan (GAPDH dan HPRT1) dalam kanser payu dara dan kolorektal apabila dibandingkan dengan kawalan, dengan $p < 0.05$ sebagai signifikan secara statistik. Kajian ini menunjukkan RNA yang diestrak adalah sangat utuh dengan $RIN > 7.0$ untuk kebergantungan analisa ekspresi gen. Ekspresi STK15 adalah berkurangan secara ketara ($p < 0.05$) dalam kolorektal, tanpa mengambil mengira perbezaan dalam kumpulan umur dan jantina. Menariknya, kekurangan signifikan ($p < 0.05$) ekspresi STK15 untuk kanser payu dara dalam umur ≥ 50 tetapi bukan dalam < 50 mencadangkan faktor kaitan umur dalam kanser payu dara dan bukan kolorektal. Tiada bukti signifikan telah ditunjukkan dalam kekurangan regulasi gen CENPW dan TIMP1 menyumbang kepada kanser payu dara dan kolorektal dalam kajian ini. Siasatan lanjut bergantung pada STK15 Phe31Ile genotip menunjukkan bahawa ekspresi STK15 dalam kanser payudara adalah berkurangan secara tidak signifikan ($p > 0.05$) selepas disusun mengikut setiap genotip masing (Phe/Phe, Phe/Ile, dan Ile/Ile) tetapi adalah berkurangan secara signifikan ($p < 0.05$) dalam kolorektal dalam genotip Phe/Phe atau Ile/Ile apabila dibandingkan dengan kawalan masing-masing. Ini menunjukkan Phe/Phe atau Ile/Ile genotip dalam STK15 Phe31Ile polimorfisme berhubung kait dalam kekurangan ekspresi STK15 dalam kanser kolorektal tetapi tidak dalam kanser payudara. Secara rumusan, kekurangan ekspresi STK15 dalam kajian ini memberi pandangan awal untuk menggunakan darah sebagai biopenanda bagi kanser payu dara dan kolorektal.

TABLE OF CONTENTS

	Page
TITLE	i
DECLARATION	ii
SUPERVISOR CONFIRMATION	iii
ACKNOWLEDGEMENT	iv
ABSTRACT	v
ABSTRAK	vi
TABLE OF CONTENTS	vii
LIST OF TABLES	xi
LIST OF FIGURES	xiii
LIST OF SYMBOLS, UNITS, AND ABBREVIATIONS	xv
LIST OF APPENDIX	xvii
CHAPTER 1: INTRODUCTION	
1.1 Background of the Study	1
1.2 Objectives	2
CHAPTER 2: LITERATURE REVIEW	
2.1 An Overview in Global Cancer Statistics	3
2.1.1 Breast Cancer (BC)	5
2.1.2 Colorectal Cancer (CRC)	6
2.2 Background of Gene Expression in BC and CRC	7
2.2.1 Serine/Threonine Kinase 15 (<i>STK15</i>)	9
a. <i>STK15</i> in BC	10
b. <i>STK15</i> in CRC	11
2.2.2 Centromere Protein W (<i>CENPW</i>)	12
a. <i>CENPW</i> in Breast Cancer and CRC	13
2.2.3 Introduction of Tissue Inhibitor of Metalloproteinase 1 (<i>TIMP1</i>)	14
a. <i>TIMP1</i> in BC	16

b.	<i>TIMP1</i> in CRC	16
2.3	Methods used in Gene Expression Studies	17
2.4	Human as a Model System Representation	18
2.4.1	Targeted Tissue: Blood	19
2.5	Other Contributory Factors which Influence Gene Expression of BC and CRC	20
2.5.1	Age	20
2.5.2	Gender	21
2.5.3	Genetic Polymorphisms of <i>STK15</i>	22
2.6	Summary of Literature Review	23

CHAPTER 3: METHODS

3.1	Transcriptome Analysis and Processing	24
3.1.1	Total RNA Quantity and Purity Determination	26
3.1.2	Total RNA Integrity Number (RIN) Determination	27
3.1.3	Reverse Transcription	28
3.2	Construction of Standard Curve for Reference and Target Genes	29
3.3	Evaluation of Genomic DNA (gDNA) Contamination	31
3.4	Determination of Stable Reference Gene in Human Blood	31
3.4.1	Software Analysis of Reference Gene Stability	32
3.5	Association of Potential Target Genes in BC and CRC	32
3.6	Genotyping of <i>STK15</i> Polymorphism	33
3.6.1	DNA Isolation from Whole Blood Using Alkaline Lysis Method	33
3.6.2	Quantitative and Qualitative Analysis of Isolated DNA	36
3.6.3	Amplification of <i>STK15</i> Gene	36
3.6.4	Restriction Fragment Length Polymorphism (RFLP)	37
3.6.5	Sequencing	39
3.7	Statistical Analysis	40
3.7.1	Mann-Whitney <i>U</i> -Test	40

CHAPTER 4: RESULTS

4.1	Demography, Quantity and Quality of Total RNA	41
4.2	Performance of Taqman [®] Gene Expression Assays	44

4.3	Evaluation of gDNA Contamination in Tempus™ Blood RNA System	46
4.4	Stability of Reference Genes	48
4.5	Differential Gene Expression Analysis	51
4.5.1	Differential Expression between Healthy Controls and BC	51
a.	Age Groups Sorted Expression in BC	52
4.5.2	Differential Expression between Healthy Controls and CRC	54
a.	Age Groups Sorted Expression in CRC	56
b.	Gender Sorted Expression in CRC	58
4.6	Genetic Polymorphism and Expression of <i>STK15</i>	60
4.6.1	PCR Amplification of <i>STK15</i> Gene	61
4.6.2	Restriction Enzyme Digestion and Direct Sequencing of <i>STK15</i> Gene	61
4.6.3	Genotype Distributions of <i>STK15</i> Polymorphism	63
4.6.4	<i>STK15</i> Expressions Sorted by <i>STK15</i> Polymorphism	64
4.6.5	<i>STK15</i> Expression of BC Sorted According to Genotypes	66
4.6.6	<i>STK15</i> Expression of CRC Sorted According to Genotypes	67
CHAPTER 5: DISCUSSION		
5.1	Blood as the Sample of Study	69
5.2	Total RNA Quality and Reverse Transcription	70
5.3	Differential Expression of Target Genes Compared with Other Studies	72
5.3.1	<i>STK15</i> Expression in BC	73
5.3.2	<i>STK15</i> Expression in CRC	76
5.3.3	<i>CENPW</i> Expression in BC	77
5.3.4	<i>CENPW</i> Expression in CRC	78
5.3.5	<i>TIMP1</i> Expression in BC	79
5.3.6	<i>TIMP1</i> Expression in CRC	81
5.4	Significance of Altered <i>STK15</i> , <i>CENPW</i> , and <i>TIMP1</i> Expression of Cancer in Different Age Groups	82
5.4.1	Expression of <i>STK15</i> , <i>CENPW</i> and <i>TIMP1</i> of BC in Two Age Groups	83

5.4.2	Expression of <i>STK15</i> , <i>CENPW</i> and <i>TIMP1</i> of CRC in Two Age Groups	84
5.4.3	Expression of <i>STK15</i> , <i>CENPW</i> and <i>TIMP1</i> of CRC in Male and Female	85
5.5	Potential Aspects of <i>STK15</i> , <i>CENPW</i> and <i>TIMP1</i> Expressions in Human Whole Blood	86
5.5.1	Autophagy Process	88
5.6	<i>STK15</i> Polymorphism and Expression	89

CHAPTER 6: CONCLUSIONS

6.1	Conclusions	90
6.2	Future Research	92

REFERENCES		93
-------------------	--	----

APPENDIX



UMS
UNIVERSITI MALAYSIA SABAH

121

LIST OF TABLES

	Page
Table 2.1: Summary of cancer cases and deaths worldwide	5
Table 2.2: Summary of cancer cases and deaths in developed and un-developed regions	5
Table 3.1: Components of RT mixture for cDNA synthesis	28
Table 3.2: Conditions for cDNA Synthesis	28
Table 3.3: List of Taqman [®] Gene Expression Assays	29
Table 3.4: qPCR Mixture for Standard Curve and Gene Expression Analysis	30
Table 3.5: Cycling conditions for qPCR	30
Table 3.6: Components of PCR Mixture for DNA Amplification	37
Table 3.7: Mixture of Restriction Enzyme Digestion	38
Table 4.1: Demography of Control and Cases	42
Table 4.2: Characteristics of Isolated Total RNA	42
Table 4.3: Efficiency and R ² of Taqman [®] Gene Expression Assays	45
Table 4.4: Percentage (%) of gDNA Contamination	48
Table 4.5: Reference Genes Output by GeNorm, NormFinder for BC	49
Table 4.6: Coefficient of Variation (CV) in <i>ACTB</i> , <i>GAPDH</i> and <i>HPRT1</i> Expression for BC	49
Table 4.7: Reference Genes Output by GeNorm, NormFinder for CRC	50
Table 4.8: Coefficient of Variation (CV) in <i>ACTB</i> , <i>GAPDH</i> and <i>HPRT1</i> Expression for CRC	50
Table 4.9: Normalized Expression and Significance of Fold Change in the Expression of <i>STK15</i> , <i>CENPW</i> and <i>TIMP1</i> of Control and BC Samples	51
Table 4.10: Mean ΔCq and Fold Change of BC by Age	53
Table 4.11: Normalized Expression and Significance of Fold Change in the Expression of <i>STK15</i> , <i>CENPW</i> and <i>TIMP1</i> of Control and CRC Samples	55

Table 4.12:	Mean ΔCq and Fold Change of Gene Expression in Different Age Group of CRC	57
Table 4.13:	Fold change of Male and Female in CRC	59
Table 4.14:	Some Genotype Scoring in This Study	62
Table 4.15:	<i>STK15</i> Genotype Distributions of Among Cases and Control Samples	64
Table 4.16:	Fold Change of Gene Expression According to <i>STK15</i> Genotype and Sample Type	65
Table 4.17:	Fold Change of <i>STK15</i> Expression According to <i>STK15</i> Genotype in BC	66
Table 4.18:	Fold Change of <i>STK15</i> Expression according to <i>STK15</i> Genotype in CRC	68
Table 5.1:	Expression of <i>STK15</i> in BC from Previous Studies	75
Table 5.2:	Expression of <i>STK15</i> in CRC from Previous Studies	77
Table 5.3:	Expression of <i>CENPW</i> in BC from Previous Studies	78
Table 5.4:	Expression of <i>CENPW</i> in CRC from Previous Studies	79
Table 5.5:	Expression of <i>TIMP1</i> in BC from Previous Studies	80
Table 5.6:	Expression of <i>TIMP1</i> in CRC from Previous Studies	82



LIST OF FIGURES

	Page
Figure 2.1: Forms of Breast Cancer.	6
Figure 2.2: CRC Progression.	7
Figure 2.3: <i>STK15</i> in Cell Cycle.	10
Figure 2.4: Schematic representation of trilaminar structure of the kinetochore.	13
Figure 2.5: Affects of MMPs and TIMP at different stages of cancer development.	15
Figure 3.1: Summary of Tempus™ Blood RNA kit protocol.	26
Figure 3.2: The brief protocols of isolation of DNA from whole blood by alkaline lysis method.	35
Figure 3.3: Primer binding site, polymorphic site and restriction enzymes recognition site of <i>STK15</i> polymorphism.	38
Figure 3.4: Restriction mapping for the production of bands upon digestion with <i>ApoI</i> restriction enzyme.	39
Figure 4.1: Electropherograms of Total RNA generated by Agilent 2100 Bioanalyzer.	43
Figure 4.2: Gel picture of Total RNA from Agilent 2100 Bioanalyzer.	44
Figure 4.3: Standard curve of pre-designed and custom Taqman® assays.	46
Figure 4.4: Histogram of Relative Fold Change in BC.	52
Figure 4.5: Histogram of Relative Fold Change in BC Sorted with Age.	54
Figure 4.6: Histogram of Relative Fold Change in CRC.	55
Figure 4.7: Histogram of Relative Fold Change in CRC Sorted with Age.	58
Figure 4.8: Histogram of Relative Fold Change in CRC of Male and Female.	60
Figure 4.9: Agarose gel electrophoresis (2%) of 165bp fragment in <i>STK15</i> gene.	61
Figure 4.10: Agarose gel electrophoresis (3%) of <i>ApoI</i> digestion products.	62
Figure 4.11: Sequencing output for three genotypes.	63

Figure 4.12: Percentage of <i>STK15</i> Genotype Distribution Frequencies of This Study.	64
Figure 4.13: Relative Fold Change According to <i>STK15</i> Genotypes.	66
Figure 4.14: Histogram of Fold Change in <i>STK15</i> Expression According to <i>STK15</i> Genotype in BC.	67
Figure 4.15: Histogram of Fold Change in <i>STK15</i> Expression According to <i>STK15</i> Genotype in CRC.	68




UMS
UNIVERSITI MALAYSIA SABAH

LIST OF SYMBOLS, UNITS, AND ABBREVIATIONS

APC	-	Adenomatous Polyposis Coli
AMP	-	Autocrine motility factor
BC	-	Breast Cancer
CCAN	-	Constitutive Centromere-associated Network
<i>CENPW</i>	-	Centromere Protein W
CG	-	Control Gene
Cq	-	Quantification Cycle
CRC	-	Colorectal Cancer
CUG2	-	Cancer-upregulated Gene 2
CV	-	Coefficient of Variation
EAC	-	Europe against Cancer
FAK	-	Focal adhesion kinase
FAP	-	Familial Adenomatous Polyposis
FISH	-	Fluorescence <i>in situ</i> hybridization
FTase	-	Farnesyl Transferase
gDNA	-	Genomic DNA
HNPCC	-	Hereditary Non-polyposis CRC Syndromes
IHC	-	Immunohistochemistry
<i>KRAS</i>	-	Kristen Rat Sarcoma Viral Oncogene
MGB-NFQ	-	Minor Groove Binder-Non Fluorescence Quencher
<i>MMP</i>	-	Matrix metalloproteinases
MRD	-	Minimal Residual Disease
PBS	-	Phosphate Buffer Saline
PCR-RFLP	-	Polymerase Chain Reaction-Restriction Fragment Length Polymorphism
PGI	-	Phosphoglucose isomerise
qPCR	-	Quantitative Real-Time PCR
R²	-	Correlation
RIN	-	RNA Integrity Number
RT	-	Reverse Transcription
SD	-	Standard Deviation

SMAD2	-	Mothers Against Decapentaplegic 2
SMAD4	-	Mothers Against Decapentaplegic 4
SNP	-	Single Nucleotide Polymorphism
STK15	-	Serine/Threonine Kinase 15
TGF-β	-	Transforming Growth Factor Beta
TIMP1	-	Tissue inhibitor of metalloproteinases 1
%	-	Percentage
μg	-	Micrograms
s	-	Seconds
mL	-	Millilitre
mM	-	Milli Molar
ng	-	Nanogram
μL	-	Microliter
μM	-	Micro Mole
xg	-	Relative Centrifugal Force
rpm	-	Rotation Per Minute
kb	-	Kilobase
bp	-	Basepair



UMS
UNIVERSITI MALAYSIA SABAH

LIST OF APPENDIX

	Page	
Appendix A	Sequences of primer and TaqMan [®] probes	121
Appendix B	Buffers and Solutions	122
Appendix C	Some electropherograms output of total RNA from Bioanalyzer 2100	125
Appendix D	Some gel image output of total RNA from Bioanalyzer 2100	129
Appendix E	Some calculation in % of gDNA contamination	130
Appendix F	Some coefficient of variation (% CV) calculation of reference genes	131
Appendix G	Bar graph of mean ΔCq ($\pm SD$) in BC	132
Appendix H	Bar graph of mean ΔCq ($\pm SD$) in CRC	133
Appendix I	Some gel image of <i>STK15</i> PCR amplification	135
Appendix J	Some gel image of <i>ApoI</i> restriction enzyme digestion	136



UMMS
UNIVERSITI MALAYSIA SABAH

CHAPTER 1

INTRODUCTION

1.1 Background of the Study

Cancer is one of the primary causative of mortality worldwide where lung cancer was leading, followed by breast cancer (BC) and colorectal cancer (CRC) in year 2012. In Malaysia, CRC is the second most prevalent among Malaysian men (14.1%) and women (10.2%) after lung cancer (Ferlay *et al.*, 2012).

BC has been reported to be more prevalent in women and is the most common cancer in Malaysian woman that accounts for 28% of total cancer incidence. Approximately, 5-10% cancer was caused by genetic inheritance (Rajnish *et al.*, 2012) indicated the importance of genetic in BC carcinogenesis. BC is highly heterogeneous due to its composition of different cell types (Kim *et al.*, 2005). Generally, BC is divided into invasive and non-invasive. However, there are subtypes of BC among these two groups. Moreover, all BC cases are tested for estrogen receptor (ER), progesterone receptor (PR) and HER2 protein expressions for prognosis prediction.

CRC develops through multiple steps and complex process. Its progression from normal epithelium to cancerous cells involved sequential acquire of multiple genomic abnormalities. Common mutated genes such as *APC*, *KRAS*, *Smad*, *p53* and other genetic mutations. The knowledge and understanding on the progression and development of CRC are well understood. However, the incidence and deaths caused by CRC remain significantly high. The socio-economic impact of cancer indicates that there is a need for more understanding of cancer especially BC and CRC.

The genetic cause of cancer, especially BC and CRC were vastly studies in genomics and gene expression studies. So far, the main approach of gene expression studies uses invasive primary biopsy sampling as the main target. However, tumour does not manifest the disease by itself but affect the whole body especially whole blood. Previous studies have showed that cancer cells (Twine *et al.*, 2003; Burczynski *et al.*, 2005), including BC (Sharma *et al.*, 2005; Aaroe *et al.*, 2010) and CRC (Nichita *et al.*, 2014; Xu *et al.*, 2014) caused the changes in the blood environment, and thus evoke response in blood cells. Whole blood collection is minimal invasive and represents the physiological state of the body. Hence, whole blood presents as an alternative sample to invasive sampling of biopsy.

The aberrant expression of genes causes the development of various cancers such as BC and CRC (Pihan *et al.*, 1998). Moreover, the uncontrolled expression of *STK15*, *CENPW* and *TIMP1* has been linked to the incidence of cancers. *STK15* and *CENPW* genes were involved in the cell division whereas *TIMP1* is involved in the inhibition of *MMP*. However, their roles remain ambiguous as reported by previous studies. To date, expression of *STK15*, *CENPW*, and *TIMP1* in whole blood of BC and CRC patients is still unknown. Therefore, we hypothesized that the expression of *STK15*, *CENPW*, and *TIMP1* in human blood samples would exhibit overexpression in BC and CRC patients when compared with healthy individual.

1.2 Objectives

The main objectives of the study are:

- (a) To extract and quantify high quality of RNA from human blood.
- (b) To determine the most stable reference genes (*ACTB*, *GAPDH*, and *HPRT1*) for BC and CRC.
- (c) To analyze the mRNA expression of *STK15*, *CENPW* and *TIMP1* in whole blood of healthy controls and BC patients as well as CRC patients.
- (d) To determine the association between the genotype of *STK15* polymorphism and the expression of *STK15*.

CHAPTER 2

LITERATURE REVIEW

2.1 An Overview in Global Cancer Statistics

Cancer is one of the leading causes of death worldwide. Cancer has accounted for approximately 14.1 million of new cases and 8.2 million of deaths in 2012 (Table 2.1) (Ferlay *et al.*, 2012). This indicated that the role of prevention, detection and treatment for cancer were crucial. In addition, cancer incidence and deaths also differ by geographical means. In 2012, less developed regions showed a higher number of new cases (58.8%) and deaths (64.9%) caused by cancer when compared with developed regions (Table 2.2). The population residing in developed regions could be aware of cancer development and preventive measure towards cancers was taken more seriously as compared to less developed regions.

The most common causative of cancer mortality were cancers of the lung (1.6 million, 19.4%), liver (0.8 million, 9.1%), and stomach (0.7 million, 8.8%). Furthermore, incidence rate in men is roughly 25% higher than in women and the most frequent number of cases differ in both genders (Ferlay *et al.*, 2012).

In year 2012 it was reported that, women have the highest incidence and mortality rates due to BC which was 25.2% and 14.7%, respectively (Ferlay *et al.*, 2012). However, there was no BC incidence and mortality reported in male. In the same year, Malaysia recorded that BC was also one of the most common cancer incidence (5410 cases, 28.0%) and death (2572 cases, 11.9%) in women.

In the same year, CRC was the third most common cancer incidence in men and second in women that comprised of 10.0% and 9.2%, respectively

(Ferlay *et al.*, 2012). Moreover, the mortality rate of CRC for men and women were 8.0% and 9.0%, respectively (Ferlay *et al.*, 2012). In Malaysia, CRC was the second most common in men (2563 cases, 14.1%) and women (1976 cases, 10.2%).

Mammogram is usually conducted as screening strategy for BC, often it requires skilled persons to handle the procedure and produces false positive that induced costs (Christiansen *et al.*, 2000). It would require a biopsy tissue to confirm the presence of cancerous cell which is highly invasive and time consuming. BC treatment involves chemotherapy, radiotherapy, or mastectomy depends on the stages of cancer. Compared to the diagnosis of BC, CRC screening and diagnosis is comparably invasive and time consuming as the gold standard of procedure is colonoscopy and confirmed by biopsy tissues. CRC treatment is similar with BC where chemotherapy, radiotherapy, or resection of certain part of the colon/rectal based on the advance of CRC.

Despite various screening and treatment strategies have been employed in the current population the incidence and mortality of BC and CRC is still alarming. Various genetic approaches have been used to study BC and CRC. However, most approach involves biopsy samples which are highly invasive procedure. Hence, this study is conducted to study the gene expression of blood obtained from BC and CRC patients, and its potential to serve as a non-invasive molecular marker in the future.

Table 2.1: Summary of cancer cases and deaths worldwide

WORLD	Male	Female	Both sexes
Population (thousands)	3557717	3496728	7054446
Number of new cancer cases (thousands)	7427.1	6663.0	14090.1
Age-standardised rate (W)	205.4	165.3	182.3
Risk of getting cancer before age 75 (%)	21.0	16.4	18.5
Number of cancer deaths (thousands)	4853.1	3547.9	8201.0
Age-standardised rate (W)	126.3	82.9	102.4
Risk of dying from cancer before age 75 (%)	12.7	8.4	10.4
5-year prevalent cases, adult population (thousands)	15362.3	17182.3	32544.6
Proportion (per 100,000)	592.0	661.4	626.7
5 most frequent cancers (ranking defined by total number of cases)	Lung	Breast	Lung
	Prostate	Colorectum	Breast
	Colorectum	Lung	Colorectum
	Stomach	Cervix uteri	Prostate
	Liver	Stomach	Stomach

Source: Ferlay *et al.*, 2012

Table 2.2: Summary of cancer cases and deaths in developed and un-developed regions

Estimated numbers (thousands)	Men		Women		Both gender	
	Cases	Deaths	Cases	Deaths	Cases	Deaths
More developed regions	3244	1591	2832	1287	6076	2878
Less developed regions	4184	3062	3831	2261	8014	5323

Source: Ferlay *et al.*, 2012

2.1.1 Breast Cancer (BC)

BC is highly heterogeneous in terms of biological and clinical. The tumour itself is composed of cells from multiple origins, such as fibroblast, endothelial, myoepithelial, immune cells and the extracellular matrix (Kim *et al.*, 2005). These complexity provide a vast challenge to characterize BC tumours. In general, there are two form of BC, non-invasive and invasive. Non-invasive cancer localizes in the mild ducts in the breast and do not grow into normal tissues beyond the breast.

They are also referred as *in situ* or pre-cancers. On the contrary, most cases of BC incidence are invasive form that has grown into normal tissues (Figure 2.1).




Figure 2.1 : Forms of Breast Cancer.

Source : breastcancer.org, Accessed on 30/2/2015

2.1.2 Colorectal Cancer (CRC)

CRC development and progression is well studied and develops through multiple steps and complex process. Its progression from normal epithelium to cancerous cells involved sequential acquire of multiple genomic abnormalities. As shown in Figure 2.2. CRC occur in three specific settings: (a) over 85% of all cases were accounted of sporadic form, familial form that constitutes approximately 10%, which include (b) familial adenomatous polyposis (FAP), and (c) hereditary non-polyposis CRC syndromes (HNPCC) (De La Chapelle, 2004). Even though the progression of CRC tumours is well studied, the incidence of CRC remains alarming.